Sonoma Pharmaceuticals Inc Revenue Growth Rates (SNOA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Sonoma Pharmaceuticals Inc   (NASDAQ: SNOA)
 

SNOA's Revenue Growth by Quarter and Year

Sonoma Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/SNOA/growth
https://api.csimarket.com/api/v1/companies/SNOA/fundamentals
https://api.csimarket.com/api/v1/companies/SNOA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
SNOA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September 7.17
1st Quarter June 6.41
FY 13.58

SNOAs Annual Revenue
Sonoma Pharmaceuticals Inc 's Revenue in the fiscal year 2026 $ 19.53 millions
Sonoma Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 14.29 millions
Sonoma Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 12.74 millions
Sonoma Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 13.27 millions
Sonoma Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 12.63 millions




SNOA Revenue second quarter 2026 Y/Y Growth Comment
Sonoma Pharmaceuticals Inc achieved in the second quarter 2026, above Company average Revenue growth of 28.11% year on year, to $ 7.17 millions.

Looking into second quarter 2026 results within Medical Equipment & Supplies industry 22 other companies have achieved higher Revenue growth. While Sonoma Pharmaceuticals Inc ' s Revenue rise of 28.11% ranks overall at the positon no. 521 in the second quarter 2026.


SNOA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September 28.11 %
1st Quarter June 59.45 %
FY   -

Financial Statements
Sonoma Pharmaceuticals Inc 's second quarter 2026 Revenue $ 7.17 millions SNOA's Income Statement
Sonoma Pharmaceuticals Inc 's second quarter 2025 Revenue $ 5.60 millions Quarterly SNOA's Income Statement


SNOA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter March -
3rd Quarter December -
2nd Quarter September 11.92 %
1st Quarter June 15.29 %
FY (Year on Year)   -


Back to SNOA Growth rate Comparisons >> Back to SNOA Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #120
Overall #521

Revenue Y/Y Growth Statistics
High Average Low
59.55 % 8.56 % -52.89 %
(Jun 30 2026)   (Dec 31 2021)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #120
Overall #521
Revenue Y/Y Growth Statistics
High Average Low
59.55 % 8.56 % -52.89 %
(Jun 30 2026)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Sonoma Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
148.22 % 4.93 % -56.3 %
(Jun 30 2017)  


SNOA's II. Quarter Q/Q Revenue Comment
Sonoma Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 11.92%, to $ 7.17 millions, from $6.41 millions in the first quarter.

Within Medical Equipment & Supplies industry 58 other companies have achieved higher Revenue quarter on quarter growth. While Sonoma Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 873.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #59
Healthcare Sector #200
Overall #873
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #59
Healthcare Sector #200
Overall #873
Revenue Q/Q Growth Statistics
High Average Low
148.22 % 4.93 % -56.3 %
(Jun 30 2017)  


SNOA's II. Quarter Q/Q Revenue Comment
Sonoma Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 11.92%, to $ 7.17 millions, from $6.41 millions in the first quarter.

Within Medical Equipment & Supplies industry 58 other companies have achieved higher Revenue quarter on quarter growth. While Sonoma Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 873.


Sonoma Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 23.49
Y / Y Revenue Growth (TTM) 38.69 %
Year on Year Revenue Growth Overall Ranking # 1078
Seqeuential Revenue Change (TTM) 7.16 %
Seq. Revenue Growth (TTM) Overall Ranking # 2315


Cumulative Revenue growth Comment
Assuming the Sonoma Pharmaceuticals Inc 's fiscal year would have ended in Sep 30 2026, Sonoma Pharmaceuticals Inc would have reprted above average annual Revenue rise of 38.69% year on year, of $ 23 millions.
This marks a slow-down of the companys growth trends and from the 47% increase in Jun 30 2026.

In the Healthcare sector 204 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 117 to 1078.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 124
Healthcare Sector # 205
Overall # 1078

Revenue TTM Y/Y Growth Statistics
High Average Low
47 %
 3.52 %
-40.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 350
S&P 500 # 2315
Cumulative Revenue growth Comment
Assuming the Sonoma Pharmaceuticals Inc 's fiscal year would have ended in Sep 30 2026, Sonoma Pharmaceuticals Inc would have reprted above average annual Revenue rise of 38.69% year on year, of $ 23 millions.
This marks a slow-down of the companys growth trends and from the 47% increase in Jun 30 2026.

In the Healthcare sector 204 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 117 to 1078.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 124
Healthcare Sector # 205
Overall # 1078

Revenue TTM Y/Y Growth Statistics
High Average Low
47 %
3.52 %
-40.68 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 124
Sector # 350
S&P 500 # 2315




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SNOA's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Sbc Medical Group Holdings Incorporated37.48%$ 37.478 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions


About Sonoma Pharmaceuticals Inc Revenue Growth Rates (SNOA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Sonoma Pharmaceuticals Inc (CIK 1367083).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001683168-26-008495
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Sonoma Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.